Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novoste hopes to win the commercial race to develop radiation treatment for restenosis

This article was originally published in Clinica

Executive Summary

For three decades radiation has been known to prevent restenosis. Companies have taken differing routes to achieve market leadership in a sector estimated to be worth between $500 million and $600 million in 2001. Analysts at Piper Jaffray say that Novoste has the most promise, but Johnson & Johnson could be the first on the US market.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT078872

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel